omniture

ShangPharma to Attend Upcoming Investor Conferences in September

2011-08-15 19:27 1265

SHANGHAI, August 15, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its senior management will be participating in the following upcoming conferences in September 2011:

Mr. Michael Hui, founder and Chief Executive Officer of ShangPharma, and William Dai, Chief Financial Officer, will be presenting at the following conferences in New York City and Boston:

-- Morgan Stanley Global Healthcare Unplugged Conference

September 13-14, 2011

New York City, NY


-- Morgan Stanley China Global Healthcare Day

September 15, 2011

Boston, MA


-- UBS Global Life Sciences Conference

September 19-21, 2011

New York City, NY



Ms. Lan Xie, Vice President of Finance and Investor Relations of ShangPharma, will be presenting at the following conference in London:

-- Jefferies London Healthcare Conference

September 27-28, 2011

London, United Kingdom



Presentation materials will be available under the Presentation section of the Company's investor relations website at http://ir.shangpharma.com.

About ShangPharma Corporation

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, please contact:


ShangPharma Corporation


In Shanghai, China

Ms. Lan Xie

VP of Finance and Investor Relations

Email: IR@shangpharma.com


Christensen


In New York:

Kimberly Minarovich

Tel: +1 917-533-3268

Email: kminarovich@christensenir.com


In Hong Kong:

Tip Fleming

Tel: +852-9212-0684

Email: tfleming@christensenir.com



Source: ShangPharma Corporation
collection